Sobi publishes Q3 2022 report
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter of 2022 July – September 2022 · Total revenue SEK 3,999 M (3,761), +6 per cent, -6 per cent at constant exchange rates (CER)1 · Haematology revenue SEK 2,619 M (2,291), +3 per cent at CER of which Elocta® SEK 1,041 M (1,035), -5 per cent at CER; Alprolix® SEK 464 M (430), +2 per cent at CER; Doptelet® SEK 543 M (400), +12 per cent at CER and Aspaveli®/Empaveli™ SEK 49 M (-) · Immunology revenue SEK 1,070 M (1,144), -22 per cent at CER of which Kineret® SEK